Premium
Cardiac magnetic resonance in heart failure with preserved ejection fraction: myocyte, interstitium, microvascular, and metabolic abnormalities
Author(s) -
Quarta Giovanni,
Gori Mauro,
Iorio Annamaria,
D'Elia Emilia,
Moon James C.,
Iacovoni Attilio,
Burocchi Simone,
Schelbert Erik B.,
Brambilla Paolo,
Sironi Sandro,
Caravita Sergio,
Parati Gianfranco,
Gavazzi Antonello,
Maisel Alan S.,
Butler Javed,
Lam Carolyn S.P.,
Senni Michele
Publication year - 2020
Publication title -
european journal of heart failure
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.149
H-Index - 133
eISSN - 1879-0844
pISSN - 1388-9842
DOI - 10.1002/ejhf.1961
Subject(s) - medicine , heart failure , cardiology , heart failure with preserved ejection fraction , ejection fraction , cardiac magnetic resonance , pathophysiology , magnetic resonance imaging , cardiac magnetic resonance imaging , cardiac myocyte , stroke volume , radiology
Heart failure (HF) with preserved ejection fraction (HFpEF) is a chronic cardiac condition whose prevalence continues to rise, with high social and economic burden, but with no specific approved treatment. Patients diagnosed with HFpEF have a high prevalence of comorbidities and exhibit a high misdiagnosis rate. True HFpEF is likely to have multiple pathophysiological causes – with these causes being clinically ill‐defined due to limitations of current measurement techniques. Myocyte, interstitium, microvascular, and metabolic abnormalities have been regarded as key components of the pathophysiology and potential therapeutic targets. Cardiac magnetic resonance (CMR) has the capability to look deeper with a number of tissue characterization techniques which are closer to the underlying specific abnormalities and which could be linked to personalized medicine for HFpEF. This review aims to discuss the potential role of CMR to better define HFpEF phenotypes and to infer measurable therapeutic targets.